Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Significant Decline in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 135,510 shares, a decrease of 44.9% from the September 15th total of 245,925 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 334,412 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, Zacks Research raised Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Sysmex Stock Down 2.1%

SSMXY opened at $11.53 on Thursday. The firm has a 50 day moving average price of $11.89 and a 200 day moving average price of $10.03. The company has a market cap of $7.01 billion, a PE ratio of 27.45 and a beta of 1.18. Sysmex has a 1 year low of $8.01 and a 1 year high of $12.90. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.53 and a current ratio of 3.40.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. The firm had revenue of $825.85 million for the quarter, compared to analyst estimates of $741.67 million. Sysmex had a net margin of 7.62% and a return on equity of 8.01%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts expect that Sysmex will post 0.41 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes in vitro diagnostic products and laboratory solutions. The company is best known for its automated hematology analyzers, which are used to examine blood cells, along with related reagents, software and support services.

Its product portfolio also includes systems for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory automation and information-management solutions.